Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 861880 of 20,252 grants

Active NON-SBIR/STTR RPGS
The Role of CD3z ITAM (Immunoreceptor Tyrosine-Based Activation Motif) diversity in CAR T cell Force and Function
NATIONAL CANCER INSTITUTE University of Utah United States 2024 – 2029

Chimeric Antigen Receptors (CARs) are a combination of an extracellular single-chain variable fragment region (scFV) that recognizes tumor protein antigens in an MHC independent ma...

$5.76M
USD
Active NON-SBIR/STTR RPGS
Maintenance of genome stability in 3D
NATIONAL CANCER INSTITUTE Columbia University Health Sciences United States 2024 – 2029

Summary Cancer cells harbor signs of genomic instability, including genome rearrangements, which can contribute to tumor development. Faithful DNA repair combats this instability a...

$5.42M
USD
Active NON-SBIR/STTR RPGS
Synthetic lethal targeting of KRAS/KEAP1 co-mutant non-small cell lung cancer
NATIONAL CANCER INSTITUTE Rush University Medical Center United States 2024 – 2029

Abstract Activating KRAS mutations occur in 20-40% of non-small cell lung cancers (NSCLCs). About 20% of the KRAS mutation tumors have co-occurring mutations of KEAP1 that are resi...

$3.4M
USD
Active NON-SBIR/STTR RPGS
Decoding glioma evolution and progression by multi-dimensional single-cell profiling
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2024 – 2027

PROJECT SUMMARY / ABSTRACT Research Plan: Tumor evolution is a fundamental obstacle to cancer treatment, as malignant cells adapt to treatment and change during progression. Unders...

$2.49M
USD
Active NON-SBIR/STTR RPGS
Adapting flow cytometry methods for early detection of acute hematologic malignancies in Kenya including the improvement of sample flow processes and technical training of personnel
NATIONAL CANCER INSTITUTE Indiana University Indianapolis United States 2024 – 2029

The ability to diagnose and classify leukemias and lymphomas (LLs), in children and young adults is limited in Kenya and most of Sub-Saharan Africa. LLs represent nearly half the c...

$5.21M
USD
Active NON-SBIR/STTR RPGS
3D bioengineered microfluidic platform for research on Ewing sarcoma bone metastasis
NATIONAL CANCER INSTITUTE Georgetown University United States 2024 – 2026

Ewing sarcoma (ES) is a pediatric malignancy, which carries adverse prognosis in its metastatic form. Bone metastases, although less common, associate with the worst clinical outco...

$4.01M
USD
Active NON-SBIR/STTR RPGS
Tumor and Host Immune signatures associated with health disparities in outcomes following GD2 immunotherapy in neuroblastoma
NATIONAL CANCER INSTITUTE Emory University United States 2024 – 2029

PROJECT SUMMARY Neuroblastoma (NB) is the most common extracranial solid tumor of childhood that leads to a disproportionate number of childhood cancer deaths and an even more disp...

$5.77M
USD
Active NON-SBIR/STTR RPGS
Targeting the ROR2/p-GSK3bS9 pathway to suppress metastasis in SMARCA4-deficient lung adenocarcinoma
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2024 – 2029

Metastatic lung cancer kills >160,000 people in the US annually, and 10%-50% of patients with surgically resected lung cancer will develop distant metastasis. There remains an u...

$5.83M
USD
Active NON-SBIR/STTR RPGS
Incidental diagnosis of clonal hematopoiesis among healthy, unrelated, hematopoietic stem cell donors: A feasibility study of psychosocial, ethical, and clinical issues
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2024 – 2026

Abstract The overall goal of this line of research is to examine the psychosocial, ethical, and clinical implications of incidental medical findings of clonal hematopoiesis (CH) in...

$4.34M
USD
Completed NON-SBIR/STTR RPGS
Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2024 – 2026

PROJECT SUMMARY Despite unprecedented clinical success of chimeric antigen receptor (CAR)-T cell therapy against tumors, widespread application is limited by lengthy and labor-inte...

$4.4M
USD
Active NON-SBIR/STTR RPGS
Modulating Intratumoral Immune Composition to Enhance Immunotherapy
NATIONAL CANCER INSTITUTE Beckman Research Institute/City of Hope United States 2024 – 2026

PROJECT SUMMARY The immediate objective of our proposal is to increase immune density within solid malignancies to rectify defects in anti-tumor immunity and maximize response rate...

$4.58M
USD
Active NON-SBIR/STTR RPGS
Mechanism and approach to inactivate mutant KRAS of lung metastatic colon cancer by RNA-ligand-displaying exosome to co-deliver dCas9--gRNA ribonucleoprotein complex and KRAS siRNA
NATIONAL CANCER INSTITUTE Ohio State University United States 2024 – 2029

PROJECT SUMMARY Targeted nanotechnologies have shown great promise in overcoming roadblocks in cancer therapeutics. Tumor metastasis has a limited response or resistance to chemoth...

$4.97M
USD
Active NON-SBIR/STTR RPGS
Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2024 – 2028

PROJECT ABSTRACT Small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC) are aggressive, high-grade neuroendocrine neoplasms (HG-NENs) that often metastasize and do...

$7.04M
USD
Active NON-SBIR/STTR RPGS
Mechanisms of DNA methylation signaling and dysregulation in colon cancer
NATIONAL CANCER INSTITUTE Van Andel Research Institute United States 2024 – 2029

PROJECT SUMMARY Colon cancer is a leading cause of cancer-related death for both men and women in the United States. Abnormal DNA methylation patterning is an epigenetic hallmark o...

$6.32M
USD
Active NON-SBIR/STTR RPGS
A large-scale quasi-experimental evaluation of added sugar warning labels in restaurants
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2024 – 2029

PROJECT SUMMARY In November 2023, New York City (NYC), NY became the first jurisdiction in the US to adopt an added sugar warning policy, which requires restaurants to display a wa...

$7.17M
USD
Active OTHER RESEARCH-RELATED
Characterizing CAFs in Metastasis as a Function of Breast Cancer Cell Phenotype
NATIONAL CANCER INSTITUTE Rice University United States 2024 – 2026

Project Summary Breast cancer (BC) is the most frequently diagnosed cancer in women. In addition, metastatic BC has a 5-year survival rate of only 27% and metastases are associated...

$622K
USD
Active OTHER RESEARCH-RELATED
Targeting drivers of tumor heterogeneity to block the progression to neuroendocrine prostate cancer
NATIONAL CANCER INSTITUTE Weill Medical Coll of Cornell Univ United States 2024 – 2027

PROJECT SUMMARY/ABSTRACT Despite advances in the development of highly effective androgen receptor (AR)-directed therapies for the treatment of men with advanced prostate cancer, a...

$1.97M
USD
Active NON-SBIR/STTR RPGS
Stomal Senescence Regulator of Tumor Immunity and Progression
NATIONAL CANCER INSTITUTE Washington University United States 2024 – 2029

Project Summary The 5-year survival rate for patients diagnosed with pancreatic ductal adenocarcinomas (PDACs) is 11%. This poor outcome is due to multiple factors, including rapid...

$6.49M
USD
Active NON-SBIR/STTR RPGS
Central mechanisms of glucocorticoid circadian rhythm dysfunction in breast cancer
NATIONAL CANCER INSTITUTE Cold Spring Harbor Laboratory United States 2024 – 2029

Project Summary Breast cancer is still the most common malignancy in women worldwide. Despite the incredible advances made in the past decades towards eliminating breast cancer, ne...

$4.56M
USD
Active OTHER RESEARCH-RELATED
Calming the Cytokine Storm: Unraveling the Biology of CRS and ICANS
NATIONAL CANCER INSTITUTE Children'S Hosp of Philadelphia United States 2024 – 2029

PROJECT SUMMARY/ABSTRACT Chimeric antigen receptor T-cells (CART) have revolutionized cancer therapy. However, CART cause two common and severe toxicities: Cytokine Release Syndrom...

$2.49M
USD